CERO (CERo Therapeutics Holdings) Net Income (Continuing Operations): $-16.31 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CERo Therapeutics Holdings Net Income (Continuing Operations)?

CERo Therapeutics Holdings CERO -22.78% Net Income (Continuing Operations) is $-16.31 Mil as of Jun. 2026. The stock has 2 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. CERo Therapeutics Holdings's Net Income (Continuing Operations) for the three months ended in Jun. 2026 was $-1.03 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was $-16.31 Mil.

CERo Therapeutics Holdings  (OTCPK:CERO) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

CERo Therapeutics Holdings Net Income (Continuing Operations) Related Terms

CERo Therapeutics Holdings Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for CERo Therapeutics Holdings's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CERo Therapeutics Holdings Net Income (Continuing Operations) Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
-10.63 -11.83 -7.29 0.00 -19.92

CERo Therapeutics Holdings Quarterly Data
Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.42 -4.86 -4.54 -5.89 -1.03

CERo Therapeutics Holdings Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-16.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $-16.31 Mil mean?
CERo Therapeutics Holdings (CERO) has a Net Income (Continuing Operations) of $-16.31 Mil as of Jun. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on CERo Therapeutics Holdings and its competitors.
Is CERo Therapeutics Holdings' Net Income (Continuing Operations) too high?
CERo Therapeutics Holdings' current Net Income (Continuing Operations) is $-16.31 Mil.
How does CERo Therapeutics Holdings' Net Income (Continuing Operations) compare to AGTX and ZVSA?
CERo Therapeutics Holdings' Net Income (Continuing Operations) of $-16.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Biotechnology company?
A good Net Income (Continuing Operations) depends on the Biotechnology industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on CERo Therapeutics Holdings and its competitors. CERo Therapeutics Holdings's current Net Income (Continuing Operations) is $-16.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CERo Therapeutics Holdings stock overvalued right now?
CERo Therapeutics Holdings (CERO) has a current Net Income (Continuing Operations) of $-16.31 Mil. The current Net Income (Continuing Operations) is $-16.31 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For CERo Therapeutics Holdings (CERO), the current Net Income (Continuing Operations) is $-16.31 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CERo Therapeutics Holdings Business Description

Address 201 Haskings Way, Suite 230, South San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. The company's molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.